Fertin Pharma's bottom line suffers as bonuses and postponed product launches bite
The top-line results are unchanged for Fertin Pharma, but the bottom line has taken a hit. Delayed product launches and a bonus paid to all employees have made their mark on the books.
by christian bundgaard, translated by catherine brett
Fertin Pharma has had an eventful 2021.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Qufora lifts long-term goals despite supply challenges
For subscribers
